2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N9359
    Toddaculin 4335-12-0 99.73%
    Toddaculin is a natural coumarin that can induce differentiation and apoptosis in leukemic cells. Toddaculin suppresses excess osteoclast activity and enhances osteoblast differentiation and mineralization. Toddaculin also exhibits anti-inflammatory activity.
    Toddaculin
  • HY-N9526
    Lyciumin B 125756-66-3 98.96%
    Lyciumin B is a cyclic peptide isolated from Lysium chinense.
    Lyciumin B
  • HY-P0266
    N-Acetyl-Ser-dAsp-Lys-Pro 127103-11-1 99.74%
    N-Acetyl-Ser-dAsp-Lys-Pro, an endogenous tetrapeptide secreted by bone marrow, is a specific substrate for the N-terminal site of ACE.
    N-Acetyl-Ser-dAsp-Lys-Pro
  • HY-P1095
    Ivachtin 745046-84-8 ≥99.0%
    Ivachtin (Caspase-3 Inhibitor VII; compound 7a) is a nonpeptide, noncompetitive and reversibl caspase-3 inhibitor with an IC50 of 23 nM. Ivachtin has modest selectivity for the remaining caspases.
    Ivachtin
  • HY-P1457
    Adrenomedullin (AM) (13-52), human 154765-05-6 99.16%
    Adrenomedullin (AM) (13-52), human is a 40 amino acid peptide, which acts as an endothelium-dependent vasodilator agent.
    Adrenomedullin (AM) (13-52), human
  • HY-P1507
    Fibrinogen Binding Inhibitor Peptide 89105-94-2 99.63%
    Fibrinogen Binding Inhibitor Peptide is a dodecapeptide (HHLGGAKQAGDV, H12), which is a fibrinogen γ-chain carboxy-terminal sequence (γ400-411). Fibrinogen Binding Inhibitor Peptide is a specific binding site of the ligand for activated glycoprotein (GP) IIb/IIIa.
    Fibrinogen Binding Inhibitor Peptide
  • HY-P3061
    [Hyp3]-Bradykinin 37642-65-2 99.73%
    [Hyp3]-Bradykinin, naturally occurring peptide hormone, is a bradykinin receptor agonist. [Hyp3]-Bradykinin interacts with B2-bradykinin receptors and stimulates inositol phosphate production in cultured human fibroblasts.
    [Hyp3]-Bradykinin
  • HY-P3769
    Prepro-ANF (56-92), human 112199-06-1 99.93%
    Prepro-ANF (56-92), human is a human atrial natriuretic factor precursor. Prepro-ANF (56-92), human is also a guanylate cyclase activator that enhances particulate guanylate cyclase activity in the renal membrane and renal unit.
    Prepro-ANF (56-92), human
  • HY-Y0106
    2,6-Dihydroxyacetophenone 699-83-2
    2,6-Dihydroxyacetophenone, a polyphenolic derivative of Acetophenone (HY-Y0989), is an orally active mTOR inhibitor. 2,6-Dihydroxyacetophenone shows antioxidant activity. 2,6-Dihydroxyacetophenone inhibits cell growth and proliferation in CRC cells. 2,6-Dihydroxyacetophenone arrests at G0/G1 phase of cell cycle, induces apoptosis and suppresses cell migration in CRC cells. 2,6-Dihydroxyacetophenone inhibits xanthine oxidase (XOD) with an IC50 of 1.24 mM. 2,6-dihydroxyacetophenone improves uric acid metabolism in hyperuricemia mice, reduces plasma cholesterol in hypercholesterolemic rats, and inhibits lipid accumulation in HFD-induced obese mice. 2,6-Dihydroxyacetophenone can be used for the study of colorectal cancer (CRC), hyperuricemia and hypercholesterolemia.
    2,6-Dihydroxyacetophenone
  • HY-Y1620
    3-(3,4-Dimethoxyphenyl)propanoic acid 2107-70-2
    3-(3,4-Dimethoxyphenyl)propanoic acid is an orally active short-chain fatty acids (SCFAs). 3-(3,4-Dimethoxyphenyl)propanoic acid stimulates γ globin gene expression, erythropoiesis in vivo and is used for the β hemoglobinopathies and other anemias.
    3-(3,4-Dimethoxyphenyl)propanoic acid
  • HY-100635
    Diacetolol 22568-64-5
    Diacetolol is an active metabolite of the beta-adrenoceptor blocking agent Acebutolol (HY-17497).
    Diacetolol
  • HY-101069
    Y-26763 127408-31-5 99.7%
    Y-26763 is a K+ channel opener and active metabolite of Y-27152. Y-26763 is an ATP-sensitive K+ (KATP) channel activator.
    Y-26763
  • HY-102029
    Sarafotoxin S6c 121695-87-2 98.19%
    Sarafotoxin S6c (SRTX-c) is a potent endothelin-B receptor agonist. Sarafotoxin S6c can cause vasoconstriction in both endothelium-intact and endothelium-denuded vessels.
    Sarafotoxin S6c
  • HY-102093
    ZD 7155hydrochloride 146709-78-6 99.88%
    ZD 7155 hydrochloride is an angiotensin II receptor type 1 (AT1 receptor) antagonist.
    ZD 7155hydrochloride
  • HY-103174
    MRS1334 192053-05-7 98.93%
    MRS1334 is a potent and selective human adenosine A3 receptor antagonist with Kis of 2.69 nM, >100 nM, >100 nM for hA3, rA1, rA2A, respectively. MRS1334 blocks the protective effect of Cl-IB-MECA leading to significant bradycardia and elevated ST segment. MRS1334 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    MRS1334
  • HY-105858
    H-Ile-Trp-OH 13589-06-5 98.04%
    H-Ile-Trp-OH (Ile-Trp), a dipeptide, is an angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 0.7 μM. H-Ile-Trp-OH inhibits predominantly the C-domain of ACE.
    H-Ile-Trp-OH
  • HY-106045
    Imazodan 84243-58-3 99.38%
    Imazodan is a selective inhibitor for phosphodiesterase III (PDE III), which increases myocardial contractility by blocking the cAMP degradation, and improves the contractile function of heart. Imazodan serves also as a peripheral vasodilator.
    Imazodan
  • HY-106130
    Implitapide 177469-96-4 99.87%
    Implitapide (AEGR 427) is a microsomal triglyceride transfer protein (MTP) inhibitor.
    Implitapide
  • HY-106181
    Rivoglitazone 185428-18-6 98.59%
    Rivoglitazone (R-106056) is an orally active, selective PPARγ agonist with an EC50 of 0.22 μM for hPPARγ. Rivoglitazone regulates fatty acid storage and uptake, glucose homeostasis, and cardiac glucose/fatty acid metabolism. Rivoglitazone reduces levels of hyperglycemia, hyperinsulinemia, and hypertriglyceridemia, decreases hepatic glucose production, and accelerates plasma triglyceride clearance. Rivoglitazone induces a reduction in glycated hemoglobin A1C, while causing peripheral edema and weight gain. Rivoglitazone can be used in research related to type 2 diabetes.
    Rivoglitazone
  • HY-106612
    Abanoquil 90402-40-7 98.07%
    Abanoquil (U-K52046), an potent and selective α-1 adrenoceptor antagonist, is an anti-arrhythmic agent. Abanoquil can be used for erectile dysfunction research.
    Abanoquil
Cat. No. Product Name / Synonyms Application Reactivity